Testosterone therapy in women with gynecological and sexual disorders: A triumph of clinical endocrinology from 1938 to 2008

Journal of Sexual Medicine

Volumn 6, Issue 2, 2009, Pages 334-351

  Traish, Abdulmaged M ^a   Feeley, Robert J ^a   Guay, Andre T ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Androgen deficiency in women's sexual disorders; Androgen therapy; Female sexual dysfunction; Testosterone

Indexed keywords

ANDROGEN; DIETHYLSTILBESTROL; ESTROGEN; METHYLTESTOSTERONE; PROGESTERONE; TESTOSTERONE PROPIONATE;

ACNE; ANDROGEN THERAPY; CARDIOVASCULAR RISK; CLITORIS SIZE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSMENORRHEA; FEMALE; FEMALE SEXUAL DYSFUNCTION; HIRSUTISM; HORMONE RESPONSE; HUMAN; LIBIDO; MASTALGIA; MASTITIS; MENOPAUSAL SYNDROME; MENORRHAGIA; MONOTHERAPY; NAUSEA; ORGAN SIZE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; UTERUS BLEEDING; UTERUS MYOMA; UTERUS TUMOR;

EID: 59349103981     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01121.x     Document Type: Review

References (111)

1. Shorr E, Papanicolaou GN, Stimmel BF. Neutralization of ovarian follicular hormone in women by simultaneous administration of male sex hormone. Proc Soc Exp Bio Med 1938;38:759-62.
2. Loeser AA. The action of testosterone propionate on the uterus and breast. Lancet 1938;1:373-4.
3. Berlind M. Oral administration of methyl testosterone in gynecology. J Clin Endocrinol 1941;1:986-91.
4. Salmon UJ. Rational for androgen therapy in gynecology. J Clin Endocrinol 1941;1:162-79.
5. Salmon UJ, Geist SH, Gaines JA, Walter RI. The treatment of abnormal uterine bleeding with androgens. Am J Obstet Gynecol 1941;41:991-1009.
6. Salmon UJ, Geist SH. Effect of androgens upon libido in women. J Clin Endocrinol 1943;3:235-8.
7. Loeser AA. Subcutaneous implantation of female and male hormone in tablet form in women. Br Med J 1940;1:479-82.
8. Greenblatt RB, Mortara F, Torpin R. Sexual libido in the female. Am J Obstet Gynecol 1942;44:658-63.
9. Rubinstein HS, Shapiro HD, Freeman W. The treatment of morbid sex craving with the aid of testosterone priopionate. Am J Psychiatry 1940;97:703-13.
10. Abel S. Androgenic therapy in malignant disease of the female genitalia. Am J Obstet Gynecol 1945;49:327-42.
11. Freed SC. Therapeutic use of testosterone in aqueous suspension. J Clin Endocrinol 1946;6:571-4.
12. Greenblatt RB. Testosterone propionate pellet implantation in gynecic disorders. J Am Med Assoc 1943;121:17-24.
13. Carter AC, Cohen CJ, Shorr E. The use of androgens in women. Vitam Horm 1947;5:317-91.
14. Hamblen EC. Rationale of androgenic therapy in gynecology. J Clin Endocrinol 1941a;1:180-6.
15. Hamblen EC, Cuyler WK, Axelson GJ. Studies on corpus luteum metabolism. Endocrinology 1941b;28:70-1.
16. Hamblen EC. Androgen therapy in women. J Clin Endocrinol 1942;2:575-6.
17. Korenchevsky V. The bisexual properties and cooperative activity of sexual hormones and their effects on females. Br Med J 1937;2:896-9.
18. Greenblatt RB, Wilcox EA. Hormonal therapy of fibromyomas of the uterus. Southern Surgeon 1941;10:339-46.
19. Kennedy BJ, Nathanson IT. Effects of intensive sex steroid hormone therapy in advanced breast cancer. J Am Med Assoc 1953;152:1135-41.
20. Studd JW, Collins WP, Chakravarti S, Newton JR, Oram D, Parsons A. Oestradiol and testosterone implants in the treatment of psychosexual problems in the post-menopausal woman. Br J Obstet Gynaecol 1977;84:314-6.
21. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: A prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47:339-51.
22. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409.
23. Sherwin BB. Sex hormones and psychological functioning in postmenopausal women. Exp Gerontol 1994;29:423-30.
24. Sherwin BB. Randomized clinical trials of combined estrogen-androgen preparations: Effects on sexual functioning. Fertil Steril 2002;77(4 suppl):S49-54.
25. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med 1998;43:847-56.
26. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM, Allolio B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013-20.
27. Arlt W, Callies F, Allolio B. DHEA replacement in women with adrenal insufficiency-pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocr Res 2000;26:505-11.
28. Waxenberg SE, Drellich MG, Sutherland AM. Changes in female sexuality after adrenalectomy. J Clin Endocrinol 1959;19:193-202.
29. Arlt W. Androgen therapy in women. Eur J Endocrinol 2006;154:1-11.
30. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-9.
31. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007a;88:1-17.
32. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: Safety issues and controversies. J Sex Med 2007b;4:859-66.
33. Bolour S, Braunstein G. Testosterone therapy in women: A review. Int J Impot Res 2005;17:399-408.
34. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-52.
35. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie DW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006a;13:387-96.
36. Davis SR. The use of androgens for female sexual dysfunction. Nat Clin Pract Urol 2006b;3:176-7.
37. Davis S, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, Stuckey BG, Wlodarczyk J, Gard'ner K, Humberstone A. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: A randomized trial. Ann Intern Med 2008a;148:569-77.
38. Davis SR, Nijland EA. Pharmacological therapy for female sexual dysfunction: Has progress been made? Drugs 2008b;68:259-64.
39. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, DeRogatis L. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007;4:1001-8.
40. Mazer NA, Shifren JL. Transdermal testosterone for women: A new physiological approach for androgen therapy. Obstet Gynecol Surv 2003;58:489-500.
41. Panjari M, Davis SR. DHEA therapy for women: Effect on sexual function and wellbeing. Hum Reprod Update 2007;13:239-48.
42. Shifren JL, Mazer NA. Safety profile of transdermal testosterone therapy in women. Am J Obstet Gynecol 2003;189:898-9.
43. Shifren JL. The role of androgens in female sexual dysfunction. Mayo Clin Proc 2004;79(4 suppl):S19-24.
44. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 Study. Menopause 2006;13:770-9.
45. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985-94.
46. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33.
47. Mazer C, Mazer M. The treatment of dysfunctional uterine bleeding with testosterone propionate. Endocrinology 1939a;24:599-602.
48. Mazer M, Mazer C. The effect of prolonged testosterone propionate administration on the immature and adult female rat. Endocrinology 1939b;24:175-81.
49. Geist SH, Salmon UJ. Androgen therapy in gynecology. J Am Med Assoc 1941;117:2207-13.
50. Rubinstein HS, Abarbanel AR. The use of testosterone propionate in the treatment of dsymenorrhea. Am J Obstet Gynecol 1939;37:709-15.
51. Cinberg BL. Androgens in the treatment of dysmenorrhea. N Y State J Med 1942;42:2138-41.
52. Gusberg SB. Androgen therapy of menopausal symptoms in cancer patients. Am J Obstet Gynecol 1945;50:502-9.
53. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod JP. Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. J. Clin Endocrinol 1950;10:1547-58.
54. Glass SJ, Shapiro MR. Androgen-estrogen treatment in the menopause. GP 1951;3:39-42.
55. Walter RI. Male hormone in the treatment of the menopause. Am J Obstet Gynecol 1953;66:375-84.
56. Taylor HC. The endocrine aspects of chronic mastitis. Surg Gynecol Obstet 1942;74:326-42.
57. Spence AW. Testosterone propionate in chronic mastitis. Lancet 1939;2:820-3.
58. Spence AW. Local injunction of testosterone in chronic mastitis. Lancet 1940;2:387-9.
59. Atkins HJB. Treatment of chronic mastitis. Lancet 1940;2:411-3.
60. Nathanson IT, Meigs JV, Parsons L. The treatment of mammary pain and secretion with testosterone propionate. N Engl J Med 1942;226:323-7.
61. Perloff WH. Influence of testosterone propionate on the size of uterine fibroids in human male. J Clin Endocrinol 1942;2:419.
62. Perloff WH, Kurzrok R Production of uterine tumors in the guinea pig by local implantation of estrogen pellets. Proc Soc Exp Biol Med 1941;46;262-5.
63. Beecham CT. Androgen therapy in pelvic malignancy. Am J Obstet Gynecol 1943;46:849-52.
64. Wyatt J. The effect of testosterone propionate on two cases of ovarian carcinoma. J Obstet Gynaecol Br Emp 1945;52:174-6.
65. Greenblatt RB, Kupperman HS. Further studies on the control of menorrhagia. J Clin Endocrinol 1946;6:675-87.
66. Graham JB, Graham RM. A method of enhancing the effectiveness of radiotherapy in cancer of the uterine cervix. Cancer 1953;6:68-76.
67. Farrow JH, Woodard HQ. The influence of androgenic and estrogenic substances on the serum calcium. J Am Med Assoc 1942;118:339-43.
68. Fels E. Treatment of breast cancer with testosterone propionate. J Clin Endocrinol 1944;4:121-5.
69. Prudente A. Postoperative prophylaxis of recurrent mammary cancer with testosterone priopionate. Surg Gynecol Obstet 1945;80:575-92.
70. Adair FE, Herrmann JB. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg 1946;123:1023-35.
71. Council on Pharmacy and Chemistry. Estrogens and androgens in mammary cancer. J Am Med Assoc 1949;140:1214-6.
72. Kurzrok R, O'Connell P. The inhibition of lactation during the puerperium by testosterone propionate. Endocrinology 1938;23:476-8.
73. Abarbanel AR. The treatment of afterpains and painful engorgement in the puerperium with testosterone propionate. Am J Obstet Gynecol 1939;38:1043-5.
74. Salonia A, Pontillo M, Nappi RE, Zanni G, Fabbri F, Scavini M, Daverio R, Gallina A, Rigatti P, Bosi E, Bonini PA, Montorsi F. Menstrual cycle-related changes in circulating androgens in healthy women with self-reported normal sexual function. J Sex Med 2008;5:854-63.
75. Burger H. The menopausal transition-endocrinology. J Sex Med 2008;5:2266-73.
76. Alder J, Zanetti R, Wight E, Urech C, Fink N, Bitzer J. Sexual dysfunction after premenopausal stage I and II breast cancer: Do androgens play a role? J Sex Med 2008;5:1898-906.
77. Kingsberg SA, Simon JA, Goldstein I. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2008;5(4 suppl):182-93.
78. Goldstein I. Editorial comments on "the current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women". J Sex Med 2008;5(4 suppl):177-8.
79. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697-710.
80. Traish A, Guay AT, Spark RF, Testosterone Therapy in Women Study Group. Are the endocrine society's clinical practice guidelines on androgen therapy in women misguided? A commentary. J Sex Med 2007;4:1223-4. discussion 1234-5.
81. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004;77:257-67.
82. Ettinger B, Fireman B. Estrogen-androgen hepatotoxicity? Am J Obstet Gynecol 1998;178:627-8.
83. Gleeson D, Newbould MJ, Taylor P, McMahon RF, Leahy BC, Warnes TW. Androgen associated hepatocellular carcinoma with an aggressive course. Gut 1991;32:1084-6.
84. Heywood R, Chesterman H, Ball SA, Wadsworth PF. Toxicity of methyl testosterone in the beagle dog. Toxicology 1977;7:357-65.
85. Taylor W, Snowball S, Lesna M. The effects of long-term administration of methyltestosterone on the development of liver lesions in BALB/c mice. J Pathol 1984;143:211-8.
86. Wason S, Pohlmeyer-Esch G, Pallen C, Palazzi X, Espuña G, Bars R. 17alpha-methyltestosterone: 28-day oral toxicity study in the rat based on the "Enhanced OECD Test Guideline 407" to detect endocrine effects. Toxicology 2003;192:119-37.
87. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet 1977;2:262-3.
88. Bird DR, Vowles KD. Liver damage from long-term methyltestosterone. Lancet 1977;2:400-1.
89. Goodman MA, Laden AM. Hepatocellular carcinoma in association with androgen therapy. Med J Aust 1977;2:20-1.
90. Nieschlag E. Is methyltestosterone no longer used therapeutically? Dtsch Med Wochenschr 1981;4:1123-5.
91. Penteado SR, Fonseca AM, Bagnoli VR, Abdo CH, Júnior JM, Baracat EC. Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women. Climacteric 2008;11:17-25.
92. de Paula FJ, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas 2007;56:69-77.
93. Dias RS, Kerr-Corrêa F, Moreno RA, Trinca LA, Pontes A, Halbe HW, Gianfaldoni A, Dalben IS. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: A double-blind controlled pilot study. Menopause 2006;13:202-11.
94. Leão LM, Duarte MP, Silva DM, Bahia PR, Coeli CM, de Farias ML. Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: A randomized study. Eur J Endocrinol 2006;154:131-9.
95. Chiuve SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women. J Clin Endocrinol Metab 2004;89:2207-13.
96. Wisniewski AB, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. Horm Res 2002;58:150-5.
97. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol (Oxf) 2002;57:209-14.
98. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002;87:1509-16.
99. Adamson DL, Webb CM, Collins P. Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. Menopause 2001;8:233-8.
100. Gitlin N, Korner P, Yang HM. Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: A meta-analysis of eight clinical trials. Menopause 1999;6:216-24.
101. Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States. Clin Ther 1997;19:1070-84.
102. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-52.
103. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: An endocrine society position statement. J Clin Endocrinol Metab 2007;92:405-13.
104. Wang C, Shiraishi S, Leung A, Baravarian S, Hull L, Goh V, Lee PW, Swerdloff RS. Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods. Steroids 2008 (in press).
105. Thienpont LM, Van Uytfanghe K, Blincko S, Ramsay CS, Xie H, Doss RC, Keevil BG, Owen LJ, Rockwood AL, Kushnir MM, Chun KY, Chandler DW, Field HP, Sluss PM. State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-tandem mass spectrometry. Clin Chem 2008;54:1290-7.
106. Swerdloff RS, Wang C. Free testosterone measurement by the analog displacement direct assay: Old concerns and new evidence. Clin Chem 2008;54:458-60.
107. Borrey D, Moerman E, Cockx A, Engelrelst V, Langlois MR. Column-switching LC-MS/MS analysis for quantitative determination of testosterone in human serum. Clin Chim Acta 2007;382:134-7.
108. Vicente FB, Smith FA, Sierra R, Wang S. Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry. Clin Chem Lab Med 2006;44:70-5.
109. Kushnir MM, Rockwood AL, Roberts WL, Pattison EG, Bunker AM, Fitzgerald RL, Meikle AW. Performance characteristics of a novel tandem mass spectrometry assay for serum testosterone. Clin Chem 2006;52:120-8.
110. Cawood ML, Field HP, Ford CG, Gillingwater S, Kicman A, Cowan D, Barth JH. Testosterone measurement by isotope-dilution liquid chromatography-tandem mass spectrometry: Validation of a method for routine clinical practice. Clin Chem 2005;51:1472-9.
111. Van Uytfanghe K, Stöckl D, Kaufman JM, Fiers T, Ross HA, De Leenheer AP, Thienpont LM. Evaluation of a candidate reference measurement procedure for serum free testosterone based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin Chem 2004;50:2101-10.